Literature DB >> 6331337

Adrenergic function in patients with panic anxiety.

R M Nesse, O G Cameron, G C Curtis, D S McCann, M J Huber-Smith.   

Abstract

Increased beta-adrenergic receptor sensitivity could account for many aspects of panic disorder. We tested this hypothesis by comparing 14 patients with six normal control subjects. The controls and eight patients had 14 blood samples taken, and heart rate and BP measured, during a four-hour protocol that included supine rest, a posture and isometric exercise stimulus, and a series of up to seven logarithmically increasing bolus intravenous doses of isoproterenol hydrochloride. The other six patients were studied only at rest. Patients had markedly elevated resting heart rate, substantially elevated levels of plasma epinephrine, cortisol, and growth hormone, mildly elevated plasma norepinephrine levels, and decreased heart rate responses to isoproterenol. These results suggest that beta-adrenergic receptor response is not increased, and may be decreased, in patients with panic disorder. Receptor down-regulation could result from the increased adrenergic function that these patients demonstrate, even in the absence of panic attacks.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331337     DOI: 10.1001/archpsyc.1984.01790190045005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  31 in total

1.  Chest pain with normal coronary arteries. Another perspective.

Authors:  J E Richter; L A Bradley
Journal:  Dig Dis Sci       Date:  1990-12       Impact factor: 3.199

2.  Increased beta-adrenergic sensitivity correlates with visceral hypersensitivity in patients with constipation-predominant irritable bowel syndrome.

Authors:  Jung Ho Park; Poong-Lyul Rhee; Hyun Seo Kim; Jun Haeng Lee; Young-Ho Kim; Jae Jun Kim; Jong Chul Rhee; Eun Ho Kang; Bum-Hee Yu
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

3.  Association of depressive and anxiety symptoms with 24-hour urinary catecholamines in individuals with untreated high blood pressure.

Authors:  Nicola J Paine; Lana L Watkins; James A Blumenthal; Cynthia M Kuhn; Andrew Sherwood
Journal:  Psychosom Med       Date:  2015 Feb-Mar       Impact factor: 4.312

4.  Anxiety and cardiovascular risk: Review of Epidemiological and Clinical Evidence.

Authors:  O Olafiranye; G Jean-Louis; F Zizi; J Nunes; Mt Vincent
Journal:  Mind Brain       Date:  2011-08

Review 5.  The Deakin/Graeff hypothesis: focus on serotonergic inhibition of panic.

Authors:  Evan D Paul; Philip L Johnson; Anantha Shekhar; Christopher A Lowry
Journal:  Neurosci Biobehav Rev       Date:  2014-03-21       Impact factor: 8.989

Review 6.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

7.  Clinically relevant cholesterol elevation in anxiety disorders: a comparison with normal controls.

Authors:  H Peter; P Goebel; S Müller; I Hand
Journal:  Int J Behav Med       Date:  1999

Review 8.  States of anxiety and their induction by drugs.

Authors:  M Lader; M Bruce
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

9.  Beta-receptor responsiveness after desipramine treatment.

Authors:  R Pohl; G N Pandey; V K Yeragani; R Balon; J M Davis; R Berchou
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Cerebral blood flow and metabolism in anxiety and anxiety disorders.

Authors:  R J Mathew
Journal:  Indian J Psychiatry       Date:  1994-07       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.